Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Catabasis Pharmaceuticals, Inc is a biotechnology business based in the US. Catabasis Pharmaceuticals shares (CATB) are listed on the NASDAQ and all prices are listed in US Dollars. Catabasis Pharmaceuticals employs 27 staff and has a market cap (total outstanding shares value) of USD$45.2 million.
|Latest market close||USD$1.89|
|52-week range||USD$1.25 - USD$8.59|
|50-day moving average||USD$1.7576|
|200-day moving average||USD$5.1072|
|Wall St. target price||USD$24|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.807|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-22.54%|
|1 month (2020-12-17)||-10.43%|
|3 months (2020-10-16)||-69.81%|
|6 months (2020-07-16)||-70.97%|
|1 year (2020-01-16)||-73.00%|
|2 years (2019-01-16)||-69.71%|
|3 years (2018-01-16)||26.85%|
|5 years (2016-01-15)||5.51|
|Gross profit TTM||USD$0|
|Return on assets TTM||-43.71%|
|Return on equity TTM||-79.77%|
|Market capitalisation||USD$45.2 million|
TTM: trailing 12 months
There are currently 469,953 Catabasis Pharmaceuticals shares held short by investors – that's known as Catabasis Pharmaceuticals's "short interest". This figure is 5.8% up from 444,224 last month.
There are a few different ways that this level of interest in shorting Catabasis Pharmaceuticals shares can be evaluated.
Catabasis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catabasis Pharmaceuticals shares currently shorted divided by the average quantity of Catabasis Pharmaceuticals shares traded daily (recently around 2.9 million). Catabasis Pharmaceuticals's SIR currently stands at 0.16. In other words for every 100,000 Catabasis Pharmaceuticals shares traded daily on the market, roughly 160 shares are currently held short.
However Catabasis Pharmaceuticals's short interest can also be evaluated against the total number of Catabasis Pharmaceuticals shares, or, against the total number of tradable Catabasis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catabasis Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Catabasis Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1126% of the tradable shares (for every 100,000 tradable Catabasis Pharmaceuticals shares, roughly 113 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catabasis Pharmaceuticals.
Find out more about how you can short Catabasis Pharmaceuticals stock.
We're not expecting Catabasis Pharmaceuticals to pay a dividend over the next 12 months.
Catabasis Pharmaceuticals's shares were split on a 1:10 basis on 31 December 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catabasis Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Catabasis Pharmaceuticals shares which in turn could have impacted Catabasis Pharmaceuticals's share price.
Over the last 12 months, Catabasis Pharmaceuticals's shares have ranged in value from as little as $1.25 up to $8.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catabasis Pharmaceuticals's is 2.1202. This would suggest that Catabasis Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.